NMRA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Neumora Therapeutics Inc (NMRA) is not a good buy for a beginner investor with a long-term strategy. The stock is facing significant negative catalysts, including failed clinical trials, a sharp decline in stock price, and workforce reductions. Additionally, technical indicators and options data do not suggest a strong buying opportunity at this time. The lack of positive financial performance and no recent congress trading data further reduce confidence in the stock's near-term recovery.
The technical indicators for NMRA are bearish. The MACD histogram is negative and contracting, RSI is neutral at 46.933, and moving averages indicate a bearish trend (SMA_200 > SMA_20 > SMA_5). Key support and resistance levels are Pivot: 1.409, R1: 1.795, S1: 1.023, R2: 2.033, S2: 0.785. The stock's price is currently below its pivot point, suggesting weakness.
Hedge funds have increased their buying activity by 327.95% over the last quarter, which could indicate some institutional confidence in the company's long-term potential.
The company faced a significant 50% drop in share price after the failure of its Phase 3 KOASTAL-2 and -3 trials for navacaprant. This led to the discontinuation of the drug's development, a 35% workforce reduction, and legal scrutiny from investors. Analysts have significantly lowered price targets, and the stock is trading at depressed levels with no clear recovery path.
No financial data is available for analysis. However, the company is undergoing cost-cutting measures, including a 35% workforce reduction, to conserve cash.
Analysts have lowered their price targets significantly following the failed trials. Mizuho reduced its target to $4 from $6, Needham to $5 from $8, and H.C. Wainwright to $7 from $18. Despite these reductions, analysts maintain Buy or Outperform ratings, citing the potential of the remaining pipeline, though it is in early stages of development.
